Plasma HER2 ( <i>ERBB2</i> ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Giulia Siravegna(University of Turin), Alberto Bardelli(IFOM), Andrea Sartore‐Bianchi(University of Milan), Salvatore Siena(University of Milan), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Livio Trusolino(University of Turin), Silvia Marsoni(IFOM), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Rebecca J. Nagy(Guardant (United States)), Justin I. Odegaard(Guardant (United States))
Clinical Cancer Research
February 26, 2019
10.1158/1078-0432.ccr-18-3389
Cited by 130

Related Papers

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
|Nature|2019|1.4k
MET signalling: principles and functions in development, organ regeneration and cancer
|Nature Reviews Molecular Cell Biology|2010|1.2k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
|Cancer Discovery|2011|948